Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04432649 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276

StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Jun 1, 2026 to Jun 1, 2027
    • Trial status changed: Recruiting → Not Yet Recruiting
    • Study description expanded, about 66 words
    • Site details revised
    v3
  2. Primary completion date: May 31, 2023 to Dec 31, 2029v2 Show 4 more changesShow less
    • Start date: Jun 1, 2020 to Jun 1, 2026
    • Study sites: 3 to 1
    • Study completion date: May 31, 2024 to Dec 31, 2030
    • Collaborators shortened, about 6 words
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Patients with refractory and/or recurrent solid tumor have poor prognosis despite complex multimodel therapy and therefore, novel approaches are urgently needed. This study attempts to treat these diseases using T cells genetically modified with a 4th generation lentiviral chimeric antigen receptor (4SCAR fused with an inducible apoptotic caspase 9 domain) targeting CD276 (B7-H3). The 4SCAR-CD276-modified T cells (4SCAR-276) can recognize and kill tumor cells through the recognition of CD276, a surface protein expressed at high levels on many types of tumors but at low levels on normal tissues. This study will evaluate the side effects and effective doses of 4SCAR-276 in treating refractory and/or recurrent tumors.
Trial Details
NCT Number NCT04432649
Lead Sponsor Shenzhen Geno-Immune Medical Institute
Conditions
(from sponsor)		 Solid Tumor
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov